Cargando…
Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy
The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple‐negative breast cancer (TNBC) patients after...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990870/ https://www.ncbi.nlm.nih.gov/pubmed/35143092 http://dx.doi.org/10.1111/cas.15273 |
_version_ | 1784683468427362304 |
---|---|
author | Eguchi, Yuki Nakai, Tokiko Kojima, Motohiro Wakabayashi, Masashi Sakamoto, Naoya Sakashita, Shingo Miyazaki, Saori Taki, Tetsuro Watanabe, Reiko Watanuki, Rurina Yamauchi, Chisako Iwatani, Tsuguo Mukohara, Toru Onishi, Tatsuya Ishii, Genichiro |
author_facet | Eguchi, Yuki Nakai, Tokiko Kojima, Motohiro Wakabayashi, Masashi Sakamoto, Naoya Sakashita, Shingo Miyazaki, Saori Taki, Tetsuro Watanabe, Reiko Watanuki, Rurina Yamauchi, Chisako Iwatani, Tsuguo Mukohara, Toru Onishi, Tatsuya Ishii, Genichiro |
author_sort | Eguchi, Yuki |
collection | PubMed |
description | The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple‐negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART‐0 (ART = 0 mm(2)), ART‐low (0 mm(2) < ART ≤ 136mm(2)), and ART‐high (ART > 136 mm(2)), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence‐free survival (RFS) or overall survival (OS) between ART‐0 and ART‐low; however, the ART‐high group had significantly shorter RFS and OS than the ART‐0 and ART‐low groups. Multivariate analysis showed that ART‐0 and ‐low and ypN(−) were independent favorable prognostic factors for RFS. Groups with both ART‐low and ypN(−) as well as those with ART‐0 and ypN(−) showed significantly longer OS and RFS than the other groups (P < .05). Moreover, there was no significant difference in the RFS and OS between the ART‐0 and ypN(−) groups and the ART‐low and ypN(−) groups (P = .249 and P = .554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART‐0 and ypN(−) (pathological complete response) and those with ART‐low and ypN(−). |
format | Online Article Text |
id | pubmed-8990870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89908702022-04-13 Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy Eguchi, Yuki Nakai, Tokiko Kojima, Motohiro Wakabayashi, Masashi Sakamoto, Naoya Sakashita, Shingo Miyazaki, Saori Taki, Tetsuro Watanabe, Reiko Watanuki, Rurina Yamauchi, Chisako Iwatani, Tsuguo Mukohara, Toru Onishi, Tatsuya Ishii, Genichiro Cancer Sci Original Articles The area of residual tumor (ART) is a prognostic factor in patients treated with neoadjuvant chemotherapy (NAC) for lung, pancreatic, and rectal cancers. This study aimed to evaluate the usefulness of ART as a method for predicting the prognosis of triple‐negative breast cancer (TNBC) patients after NAC. We included 143 patients with TNBC treated with NAC. The ART at the maximum cut surface of the residual tumor was measured. We divided the patients into three groups: ART‐0 (ART = 0 mm(2)), ART‐low (0 mm(2) < ART ≤ 136mm(2)), and ART‐high (ART > 136 mm(2)), and compared their clinicopathologic factors and prognosis. There were no significant differences in either recurrence‐free survival (RFS) or overall survival (OS) between ART‐0 and ART‐low; however, the ART‐high group had significantly shorter RFS and OS than the ART‐0 and ART‐low groups. Multivariate analysis showed that ART‐0 and ‐low and ypN(−) were independent favorable prognostic factors for RFS. Groups with both ART‐low and ypN(−) as well as those with ART‐0 and ypN(−) showed significantly longer OS and RFS than the other groups (P < .05). Moreover, there was no significant difference in the RFS and OS between the ART‐0 and ypN(−) groups and the ART‐low and ypN(−) groups (P = .249 and P = .554, respectively). We concluded that ART is a candidate histopathological evaluation method for predicting the prognosis of TNBC patients treated with NAC. Furthermore, postoperative chemotherapy could be omitted in patients with ART‐0 and ypN(−) (pathological complete response) and those with ART‐low and ypN(−). John Wiley and Sons Inc. 2022-03-01 2022-04 /pmc/articles/PMC8990870/ /pubmed/35143092 http://dx.doi.org/10.1111/cas.15273 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Eguchi, Yuki Nakai, Tokiko Kojima, Motohiro Wakabayashi, Masashi Sakamoto, Naoya Sakashita, Shingo Miyazaki, Saori Taki, Tetsuro Watanabe, Reiko Watanuki, Rurina Yamauchi, Chisako Iwatani, Tsuguo Mukohara, Toru Onishi, Tatsuya Ishii, Genichiro Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
title | Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
title_full | Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
title_fullStr | Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
title_full_unstemmed | Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
title_short | Pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
title_sort | pathologic method for extracting good prognosis group in triple‐negative breast cancer after neoadjuvant chemotherapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990870/ https://www.ncbi.nlm.nih.gov/pubmed/35143092 http://dx.doi.org/10.1111/cas.15273 |
work_keys_str_mv | AT eguchiyuki pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT nakaitokiko pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT kojimamotohiro pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT wakabayashimasashi pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT sakamotonaoya pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT sakashitashingo pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT miyazakisaori pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT takitetsuro pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT watanabereiko pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT watanukirurina pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT yamauchichisako pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT iwatanitsuguo pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT mukoharatoru pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT onishitatsuya pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy AT ishiigenichiro pathologicmethodforextractinggoodprognosisgroupintriplenegativebreastcancerafterneoadjuvantchemotherapy |